Current Concepts on the Pathogenesis of Type 1 Diabetes—Considerations for Attempts to Prevent and Reverse the Disease

Diabetes Care 2015;38:979–988 | DOI: 10.2337/dc15-0144

HISTORICAL MODEL OF TYPE 1 DIABETES PATHOGENESIS

It may be considered unusual to consider a period of three decades “historical.” Yet, the evolution for our understanding of the natural history and pathogenesis of type 1 diabetes has been greatly advanced by a vast number of studies aimed at validating a model (1), proposed by the late Dr. George Eisenbarth in 1986 (2). As a result of this work, the majority of current conventional wisdom portrays type 1 diabetes as a T cell–mediated autoimmune disease involving the specific destruction of insulin-producing pancreatic β-cells.

In this model, persons destined to develop type 1 diabetes are assumed to begin life with a full cadre of β-cells. However, a “triggering” insult, likely environmental, initiates a process involving the recruitment of antigen-presenting cells. Antigen-presenting cells sequester self-antigens released by injured β-cells, followed by their transport to pancreatic lymph nodes where they are subsequently presented to autoreactive T cells. These T cells, rogue constituents brought to life due to genetically driven failures of thymic deletion (i.e., central tolerance) combined with defects in mechanisms designed to induce peripheral immune tolerance, come into play (3). This toxic duo, imparting lack-of-tolerance formation, again in the context of genetic susceptibility, allows for migration of self-reactive T cells to islets, mediating β-cell killing and promoting further inflammation (4). When 85–90% of pancreatic β-cells meet their demise, symptoms of the disease occur. In the final stage of the model, the autoimmune process ends with the complete elimination of β-cells.

While this concept still forms the prevailing intellectual dogma for the majority of individuals associated with diabetes care and research today, a series of recent observations has challenged multiple aspects of this long-standing model (5). Many of these evolving concepts will be presented in this Perspective, with a discussion of how our understanding of models of type 1 diabetes pathogenesis has and will likely continue to evolve as it relates to attempts seeking to prevent and/or reverse the disorder.

HOW HISTORICAL MODELS GUIDED PREVENTION AND REVERSAL STUDIES AND, POTENTIALLY, THEIR FAILURES

The timing for introduction of the Eisenbarth model appeared therapeutically “fortuitous” in its day. Contemporaneous with positing autoimmunity as the formative cause of type 1 diabetes in the 1980s were therapeutic interventions developed for organ transplantation. This research brought forward a series of immunosuppressive agents thought clinically promising for multiple immune based–disorders, including type 1 diabetes. The earliest of the immunosuppressive-based studies in type 1 diabetes, using agents such as cyclosporine or azathioprine, provided evidence that preservation of endogenous insulin secretion was possible, even if only for a relatively short period of time, in settings of recent-onset disease. Such news brought hope that a means to prevent or cure type 1 diabetes was on the horizon. While adverse effects of these agents brought a close to their use in type 1 diabetes,
they set the stage for a multidecade effort to utilize a variety of biologics to target autoimmunity for the purpose of stemming the tide of β-cell destruction.

Clinical trials seeking to meet the goal of type 1 diabetes prevention (Table 1) (recently reviewed in refs. 6–9) in the case of autoantibody-positive subjects with type 1 diabetes or C-peptide preservation in recent-onset subjects (Table 2) (recently reviewed in ref. 10) have been quite variable in terms of their "success." While some trials have demonstrated the ability to either delay progression to type 1 diabetes or preserve C-peptide production in individuals with recent-onset type 1 diabetes, the vast majority of such efforts has either failed to meet the predetermined end points, or even when demonstrating early success (i.e., meeting goals of C-peptide production at 12 months for subjects with type 1 diabetes), loss in C-peptide production eventually occurs for most. Mechanistic studies affiliated with these efforts have, to a large extent, failed to identify specific mechanisms associated with therapeutic failure or success. The failures in achieving therapeutic success in humans stand in stark contrast to the results of studies in the NOD mouse, where methods capable of preventing type 1 diabetes and/or reversing overt hyperglycemia abound (11–13). We would suggest that many of the failures of human studies have been the by-product of having a poor understanding of the complexity of the disorder's pathogenesis—too many factors have historically been underappreciated, misunderstood, or unknown in considerations of the pathogenesis of type 1 diabetes (Table 3).

EMERGING VIEWS ON THE ROLE FOR IMMUNE RESPONSES IN TYPE 1 DIABETES

Perhaps no segment of the historical model for type 1 diabetes pathogenesis has been as rigorously investigated as that of the immune response of persons with or at various levels of risk for the disease. While such studies have yielded success stories with practical outcomes (e.g., autoantibody staging for disease risk, biomarker development, identification of subjects for disease prevention trials), they all suffer from a variety of limitations. By their nature, nearly all studies of human immune responses involve analysis of peripheral blood rather than at the site of β-cell destruction. In addition, while the potential importance of the so-called effector and regulatory components in type 1 diabetes pathogenesis have been extensively studied, only recently have serious considerations been given to the effects of aging, diet, immune cell metabolism, microbial pathogens, microbiomes, and epigenetic changes on the immune response affording this disease (Table 3) (14–18). These factors, individually and in combination, clearly influence immune responses in general and, thus, must be associated by default with the pathogenesis of type 1 diabetes.

As a number of type 1 diabetes reviews have recently been published highlighting features of the immune response in peripheral blood (4,19,20), this Perspective will focus on studies of human pancreas and other tissues obtained from organ donors with or at risk for type 1 diabetes that have largely, but not exclusively, been made possible through the efforts of the Belgian Beta Cell Bank and the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD) program (21,22).

Immunological Characteristics of the Pancras in Type 1 Diabetes—Evidence for Disease Subtypes

Recent studies of human pancreata have added support to the growing

---

**Table 1—Prevention trials in type 1 diabetes**

| Study name       | Intervention            | 1’Outcome               | End point achieved | Reference or ClinicalTrials.gov identifier |
|------------------|-------------------------|-------------------------|--------------------|------------------------------------------|
| **Primary prevention studies** |
| NIP              | Dietary docosahexaenoic acid | Pilot study            | — **               | 60                                       |
| Finnish TRIGR pilot | Hydrolyzed casein formula | Autoantibodies         | Yes                | 61                                       |
| BABYDIET         | Delayed dietary gluten exposure | Autoantibodies         | No                 | 62                                       |
| TRIGR            | Hydrolyzed casein formula | Autoantibodies         | No                 | 63                                       |
| FINDIA           | Whey-based, insulin-free bovine milk formula | Autoantibodies         | Yes                | 64                                       |
| **Secondary prevention studies** |
| DENIS            | Nicotinamide            | Diagnosis of type 1 diabetes | No                 | 65                                       |
| DPT-1 Parenteral Insulin | Parenteral insulin | Diagnosis of type 1 diabetes | No                 | 66                                       |
| INIT I           | Intranasal insulin      | Safety                  | Yes#               | 67                                       |
| ENDIT            | Nicotinamide            | Diagnosis of type 1 diabetes | No                 | 68                                       |
| DPT-1 Oral Insulin | Oral insulin           | Diagnosis of type 1 diabetes | No                 | 69                                       |
| DIPP sibling cohort | Intranasal insulin      | Diagnosis of type 1 diabetes | No                 | 70                                       |
| DIPP birth cohort | Intranasal insulin      | Diagnosis of type 1 diabetes | No                 | 70                                       |
| Belgian Parenteral Insulin | Parenteral insulin | Diagnosis of type 1 diabetes | No                 | 71                                       |
| TrialNet Oral Insulin | Oral insulin           | Diagnosis of type 1 diabetes | *                  | NCT00419562                               |
| INIT II          | Intranasal insulin      | Diagnosis of type 1 diabetes | *                  | NCT00336674                               |
| DIAPREV-IT       | GAD-alum (Diamyd)       | Diagnosis of type 1 diabetes | *                  | NCT01122446                               |
| TrialNet Teplizumab | Teplizumab             | Diagnosis of type 1 diabetes | *                  | NCT01030861                               |
| TrialNet Abatacept | CTLA4Ig (abatacept)    | Diagnosis of type 1 diabetes | *                  | NCT01773707                               |

Adapted with permission from Skyler (9). DENIS, Deutsche Nicotinamide Intervention Study; DIAPREV-IT, Diabetes Prevention—Immune Tolerance; DIPP, Type 1 Diabetes Prediction and Prevention Project; DPT-1, Diabetes Prevention Trial—Type 1; ENDIT, European Nicotinamide Diabetes Intervention Trial; FINDIA, Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes; INIT, Intranasal Insulin Trial; NIP, Nutritional Intervention to Prevent Diabetes; TRIGR, Trial to Reduce IDDM in the Genetically at Risk. *Data not yet available. **Pilot study. #No adverse events.
## Table 2—Reversal trials in type 1 diabetes

| Study name                                                                 | Treatment(s)                                                                 | C-peptide at 1 year (nmol/L) | Preservation of C-peptide | Reference |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------|---------------------------|-----------|
| Cyclosporin Treatment in Children with Recent-Onset Type 1 Diabetes       | Cyclosporin A                                                                | 0.3                          | Yes*                      | 72        |
| Continuous Insulin Infusion Throughout the First Two Weeks Following Type 1 Diabetes Onset | Intensive insulin therapy                                                    | 0.5                          | Yes                       | 73        |
| IMIDIAB IV                                                                | Vitamin E                                                                     | 0.2                          | Yes                       | 74        |
| IMIDIAB VI                                                                | Nicotinamide                                                                  | 0.2                          | Yes                       | 75        |
| Diabète Insuline Orale                                                   | Oral insulin                                                                  | 0.1                          | No                        | 76        |
| DIA-AID2                                                                  | DiaPep277                                                                     | 0.2                          | Yes                       | 77        |
| AbATE                                                                    | hOKT3gamma1(Ala-Ala)                                                          | 0.2                          | Yes                       | 78        |
| Diazoxide Treatment in Children with New-Onset Type 1 Diabetes           | Diazoxide                                                                    | 0.2                          | Yes                       | 79        |
| The Use of Polyclonal Anti–T-Lymphocyte Globulin to Prevent Progression of Autoimmune β-Cell Destruction in Recent Type 1 Diabetes | ATG                                                                          | 0.2                          | Yes                       | 80        |
| IMIDIAB IX                                                                | Nicotinamide + vitamin E                                                     | 0.2                          | Yes**                     | 81        |
| IMIDIAB (retrospective analysis)                                          | Nicotinamide + intensive insulin therapy                                     | 0.1                          | Yes**                     | 82        |
| TTEDD                                                                    | ChAglyCD3 (otelixizumab)                                                     | 0.5                          | Yes                       | 83        |
| Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes | hOKT3gamma1(Ala-Ala)                                                         | 0.2                          | Yes                       | 84        |
| IMIDIAB XI                                                                | Calcitriol + nicotinamide                                                    | 0.1                          | No                        | 85        |
| DIA-AID2                                                                  | DiaPep277                                                                    | 0.2                          | Yes§                      | 86        |
| Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus | AHSCFT                                                                      | 0.3                          | Yes                       | 87        |
| Phase II Trial of DiaPep277 in Children with New-Onset Type 1 Diabetes    | DiaPep277                                                                    | 0.2                          | No                        | 88        |
| DIA-AID2                                                                  | DiaPep277                                                                    | 0.4                          | Yes (trend)#              | 89        |
| A Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus | GAD-alum                                                                    | 0.1                          | No                        | 90        |
| Phase II Multiple Dose Treatment of Type 1 Diabetes Mellitus With hOKT3gamma1(Ala-Ala) | Teplizumab                                                                  | 0.8                          | Yes (trend)               | 91        |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of NBI-6024 In Adult and Adolescent Patients With New Onset Type 1 Diabetes Mellitus | NBI-6024                                                                    | 0.1                          | No                        | 92        |
| Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus | AHSCFT                                                                     | AUC = 30                     | Yes                       | 53        |
| Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects | Rituximab                                                                   | 0.1                          | Yes¥                      | 93        |
| ENBREL (Etanercept) Administration to Patients Newly Diagnosed With Type 1 Diabetes Mellitus: Feasibility-Safety Study | Etanercept                                                                  | 0.4                          | Yes                       | 94        |
| Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients | ChAgly CD3                                                                  | AUC = 0.9                    | Yes#                      | 95        |
| Efficacy of 6 Months Treatment With Diazoxide at Bedtime in Preventing β-Cell Demise in Newly Diagnosed Type 1 Diabetes | Diazoxide                                                                   | 0.1                          | No                        | 96        |
| Immunointervention With 1,25-dihydroxyvitamin D3 in New-Onset Type 1 Diabetes | 1,25(OH)2D3                                                                | 0.1                          | No                        | 97        |

*Continued on p. 982*
concept that subtypes of type 1 diabetes truly exist. For example, when histological studies of type 1 diabetes pancreata are combined, patients with disease onset at age 0–14 years and within 1 year of diagnosis show more inflamed islets (68%) and fewer islets with residual β-cells (39%) than do patients with onset at 15–39 years of age (23). This suggests a more vigorous autoimmune response occurs when disease develops in young children.

Additional evidence in support this concept was the recent finding that younger age of onset is associated with higher levels of CD20+ B cells, CD45+ cells, and CD8+ T cells in insulitis lesions, with fewer insulin-positive islets (15,24). Conversely, infiltrates with fewer CD20+ cells were observed in patients with type 1 diabetes who were

### Table 2—Continued

| Study name                                                                 | Treatment(s)                  | C-peptide at 1 year (nmol/L) | Preservation of C-peptide | Reference |
|---------------------------------------------------------------------------|-------------------------------|------------------------------|--------------------------|-----------|
| Protége study                                                             | Teplizumab                    | 0.5                          | Yes#                     | 98        |
| TrialNet GAD                                                              | GAD-alum                      | 0.3                          | No                       | 99        |
| TrialNet Abatacept                                                        | Abatacept                     | 0.3                          | No                       | 100       |
| DIATOR                                                                    |                                |                              |                          |           |
| Efficacy of ATG + Autologous CD34+ Stem Cells + GCSF in New-Onset Type 1 Diabetes<sup>6</sup> | Mobilized hematopoietic CD34+ stem cells | 0.4                          | Yes         | 102       |
| A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (EU) | GAD-alum                      | 0.3                          | No                       | 103       |
| DIATOR                                                                    | Atorvastatin                  | 0.2                          | Yes†                     | 104       |
| Prospective Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes |                                |                              |                          |           |
| Safety and Efficacy Study of Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes—A Phase II Study | AHSCT                          | 0.6                          | Yes                      | 105       |
| A Phase I Trial of Proleukin and Rapamune in Recent-Onset Type 1 Diabetes Mellitus (ITN018A1) | Rapamycin/interleukin (IL)-2 | AUC = 6.3                    | No                       | 107       |
| Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes (anti-IL-1)/ Anti-Interleukin-1 in Diabetes Action | Canakinumab/Anakinra          | 0.1                          | No                       | 108       |
| Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin) and Pegylated GCSF (Neulasta) in Established Type 1 Diabetes | ATG + GCSF                    | 0.74                         | Yes                      | 54        |

Adapted with permission from Ben Nasr et al. (10). AbATE, Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes; AHSCT, autologous hematopoietic stem cell transplantation; ATG, anti-T-lymphocyte globulin; AUC, area under the curve; DIA-AID, Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults; DIATOR, Diabetes Intervention With Atorvastatin; GCSF, granulocyte-colony stimulating factor; IMDiAb, Immunootherapy of DIABetes; TTED, TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM).◆Defined as author-reported interpretation. *Official study name could not be determined. **Effect lost on withdrawal of treatment. ***No synergistic benefit with combination. §Differential outcomes depending on dose. #Differential effects depending on age-group. ¥Reported partial preservation of β-cell function. *Differential effects depending on baseline C-reactive protein concentrations.

### Table 3—Features influencing the pathogenesis and natural history of type 1 diabetes likely underappreciated in therapeutic trials seeking to prevent and or reverse the disease

| Immune                              | Pancreas/β-Cells | Environment/Genetics |
|-------------------------------------|------------------|---------------------|
| Innate immunity                     | Small pancreas   | Microbiome (gut, oral) |
| Influence of age on immune response | Vascular abnormalities | Diet               |
| Immune cell metabolism              | Pancreatitis (role) | Antibiotic use      |
| Acute versus chronic β-cell destruction | Exocrine infiltration | Exercise           |
| Limited/focal nature of insulitis   | β-Cell replication as a function of age | Epigenetic modifications |
|                                     |                  | Relationship with gut (including celiac disease) |
Emerging features regarding pancreatic islets in type 1 diabetes. Recent descriptions of insulin (23,25,51,55) have placed an emphasis on the quantitative differences in this lesion when comparing human pancreatic samples to those observed in the NOD mouse model of disease. For example, the intensity and pattern of lymphocytic infiltration in NOD mice at or immediately prior to disease onset (A; 14-week-old new-onset case) is quite pronounced relative to that of human type 1 diabetes (B; 13-year-old with type 1 diabetes <1 year, nPOD 6228). C: Consistent with a notion ascribing a role for viral infections with type 1 diabetes, an nPOD organ donor from a patient with disease onset at 10.2 years of age and a 4-year duration was examined. An islet from this donor expressed abundant insulin (blue), CVB capsid protein VP1 (green), and MDAS (red) in islet cells. β-Cells expressing both MDAS and insulin are purple. This islet was also negative for CD45 staining, demonstrating a lack of insulitis (representative image = 40×).
with the more widely studied rodent islet, including dissimilarities in islet cell composition, basal insulin secretion, susceptibility to toxins such as streptozotocin, amyloid formation, and cell proliferation (39–42).

In response to the increased metabolic demands of insulin resistance and obesity, rodent β-cells increase insulin biosynthesis and cellular proliferation, leading to a marked increase in β-cell mass. In contrast, pancreatic samples from obese humans show only a minimal or modest expansion in β- or islet-cell mass (43). These differences between rodent and human islets do not invalidate rodent models of islet biology but require increased attention and integration of findings in rodents to human islets and the human pancreas.

**β-Cell Mass Is Not Equal in All Individuals**

Historical models of type 1 diabetes have assumed a normal β-cell mass at birth that declines once the autoimmune attack occurs. However, recent studies of cadaveric pancreata have shown that β-cell mass in normal humans without diabetes varies three- to fivefold, independent of adult age or BMI, with β-cell mass likely mostly determined in the first two decades of life (43–45). This has important implications when one considers the starting point for declining β-cell mass during autoimmune β-cell destruction. Thus, an individual’s timeline to diabetes onset could be determined not by the severity of the autoimmune attack but the starting point for β-cell mass (Fig. 2). The reasons for this variation in β-cell mass are unknown but could include the in utero environment, events during the first decade of life, and yet unknown genetic or environmental determinants. Further emphasizing the need to understand the timeline and determinants of human β-cell mass is the recent observation of a smaller pancreatic mass in individuals with new-onset type 1 diabetes or with islet-cell autoantibodies (46,47). This observation raises the possibility that determinants of both pancreatic mass and β-cell mass might be impacted, as endocrine islet cells and exocrine cells share a common embryologic heritage.

**Are All β-Cells Equally Susceptible to Destruction in Type 1 Diabetes?**

It has also been assumed that all human β-cells are equally susceptible to autoimmune attack and that differences in the timeline of type 1 diabetes pathogenesis relate to immune differences. In reality, variations in β-cell susceptibility to cytokines or immune cell attack could be an important determinant of when an individual develops clinical diabetes (Fig. 2). While certain immunomodulatory approaches appear to improve C-peptide production (6), improved β-cell function is not synonymous with prevention of β-cell loss or recovery of β-cell mass. An ongoing debate surrounding type 2 diabetes is whether loss of β-cell function or reduction in mass is the reason for inadequate insulin secretion, but most agree that both pathogenic processes are important. In addition, metabolic derangements clearly impact key islet-enriched transcription factors or may promote loss of β-cell identity (48,49). Therefore, potential parallels with β-cell dysfunction and/or loss in type 1 diabetes seem clear. A challenge is that there are no markers (other than insulin secretion) or noninvasive imaging modalities that reflect β-cell mass in humans. As insulin secretion (basal or stimulated as part of the intravenous glucose tolerance test, oral glucose tolerance test, or mixed-meal tolerance test) can be affected by chronic elevations in the blood glucose and secretory capacity has not been shown to truly correlate closely with β-cell mass over time, improvements in how to assess β-cell mass in humans are needed.

**Subjects With Long-standing Type 1 Diabetes, in Fact, Have β-Cells**

One of the longer-standing dogmas in type 1 diabetes is that eventually all β-cells are lost in long-standing disease, but the emerging reality is quite different. Many individuals with type 1 diabetes produce small amounts of C-peptide, and studies of the pancreata from individuals with type 1 diabetes show the presence of insulin-positive cells, sometimes within glucagon-rich islets or as single insulin-positive cells scattered throughout the pancreatic exocrine tissue (24,26,50). Interestingly, C-peptide levels were higher in patients >18 years of age at onset and with shorter duration of diabetes (26). These findings raise the question of why some β-cells escape the autoimmune attack or are somehow resistant to it. Are the surviving β-cells somehow “different”? Alternatively, new β-cells may be constantly being regenerated and subsequently destroyed by the ongoing autoimmune process. Now that the transcriptional profile and molecular signatures of normal human β-cells are being defined, it should be possible to determine whether these residual insulin-positive cells are “normal” β-cells.
Inducing Human β-Cells to Proliferate

Intense efforts to induce human β-cell proliferation are under way and our improved understanding of human β-cell biology is providing clues regarding signaling pathways and cell cycle determinants important for human β-cell proliferation (42–44). As recently summarized, we currently lack an approach to induce sustained human β-cell proliferation with an acceptable safety profile (42). A clear challenge is the need to induce only β-cell proliferation as many of the current approaches and growth factors being tested target pathways present in many cell types. The ability to specifically target β-cells in vivo with either a proliferative signal or a protective intervention is needed. Moreover, successful strategies in prevention of type 1 diabetes and/or in preservation of β-cell function may require interventions targeting immune pathways in combination with approaches that promote β-cell proliferation (Fig. 3).

HOW KNOWLEDGE REGARDING THE PATHOGENESIS AND NATURAL HISTORY OF TYPE 1 DIABETES IS VITAL FOR EFFORTS TO PREVENT AND REVERSE THE DISEASE

When and How Fast Are β-Cells Lost in Type 1 Diabetes and Is It a True Loss That Occurs or a Mere Loss of Their Function?

At odds with studies of NOD mice (Fig. 1A), it has been difficult to document insulitis in many type 1 diabetes cases during the prediabetic phase (Fig. 1B), when individuals already have clear signs of autoimmunity (51). This observation implies that attacks on β-cells likely occur in a relapsing-remitting fashion (52). As currently available biomarkers fail to indicate precisely when periods of attack occur, such periods could be missed with short-term therapies. Therefore, future trials should consider longer-term treatment periods or utilization of agents whose effects would be lasting (e.g., tolerance inducing). However, agents used for long-term treatment must also avoid adverse side effects in order to gain widespread acceptance.

It has also recently become apparent that β-cell mass does not decrease in a linear fashion (T. Rodriguez-Calvo, K. Herold, M.A.A., and M.v.H., unpublished data). Indeed, substantial β-cell mass might still be present until just prior to the time when oral glucose tolerance testing becomes abnormal. This latter observation is potentially encouraging in that more β-cells may be present than once thought prior to diagnosis. As a result, efforts to preserve β-cell mass and metabolic capacity in settings of secondary disease prevention might have more potential for success than previously assumed.

Questions also abound regarding the degree of β-cell function (or lack thereof) following diagnosis of the disease. It was previously thought that approximately 90% of β-cell mass and function are irrevocably lost by the time type 1 diabetes is diagnosed. However, we now know that strong immune suppression can result in a rather rapid recovery of β-cell function (53). Factors that contribute to reduced β-cell function at the time of diagnosis include inflammatory stress, excessive demand for insulin, and endoplasmic reticulum stress—deleterious processes that are at least in part reversible. Furthermore, as noted previously, many adults with type 1 diabetes of extended duration still retain a degree of C-peptide production (54). This realization points toward the possibility that maintenance of remaining β-cell function in adults, even many years postdiagnosis, may provide clinical benefit.

Nature of the Beast—Who Attacks and Destroys the β-Cells and How Do We Need to Deal With It?

The most prominent cell found in human islets in the setting of type 1 diabetes is the CD8⁺ cytotoxic T cell, which is also a likely candidate to aid in β-cell killing due to its ability to recognize targets via antigen in the context of MHC class I, which is elevated in many islets in those with the disease (55). Therapeutically, lymphocytes and memory lymphocytes of the adaptive immune response can be targeted by anti–T-cell drugs, such as anti-CD3, anti-CD2 (LFA3lg), and certain costimulatory blockers (56,57). Indeed, partial success of such compounds in recently diagnosed type 1 diabetes, defined by preservation of β-cell function (i.e., C-peptide production) over several months to years, speaks toward an important role for such autoreactive lymphocytes in β-cell destruction, at least late during the pathogenesis of type 1 diabetes.

Are β-cell antigen-specific CD8⁺ T cells the only factor? Certainly not, as it has become clear that general low-grade inflammation can be observed in the exocrine pancreas and inflammatory cytokines known to harm islets are also thought to be elevated during type 1 diabetes pathogenesis. Thus, anti-inflammatory therapies targeting cytokines may hold promise, and a recent trial blocking tumor necrosis factor has shown initial promise in preserving β-cells (58). These observations provide further support for the concept of combination therapies. Examples of such combinations would include an induction component using drugs targeting

![Figure 3](image-url)
inflammation and T-/B-cell memory, as well as a maintenance component that could involve antigens to induce tolerance to β-cells.

One additional important question involves how the β-cell appears on the radar screen of the immune system in the first place. Is autoimmunity the primary cause, or might it be that metabolic derailing exerts stress on β-cells and in this way makes them visible to the immune system? In reality, this might at least be a contributing factor to the pathogenesis of type 1 diabetes and type 2 diabetes, as metabolic markers can precede the diagnosis of the former by several years. Considering this, priority should be given to the addition of drugs to combination therapies that stabilize and maintain β-cells and β-cell function (Fig. 3).

CONCLUSIONS AND FUTURE DIRECTIONS

Within a few years, those involved in the care of persons with type 1 diabetes as well as researchers seeking to make impactful discoveries for those living with the disease will celebrate the centennial anniversary of the discovery of therapeutic insulin. Thankfully, the era since that monumental event has seen a multitude of improvements in diabetes care (59). At the same time, significant research efforts have been directed at finding the underlying cause(s) of type 1 diabetes, in large part guided by the notion of developing a means to prevent as well as provide a true “cure” for the disease. While progress has clearly been made toward understanding the initiating and sustaining events in the pathogenesis of type 1 diabetes (Fig. 2), much more investigation and discovery are needed. We believe that future attempts to prevent and/or reverse type 1 diabetes are most likely to be successful if they incorporate the recent advances in our evolving understanding of pathogenesis of the disease.

Acknowledgments. The authors would like to thank Dr. Amanda Posgai for her remarkable editorial efforts toward publication of the manuscript.

Funding. Concepts that underlie much of the communication were developed through research supported by JDRF (25-2013-268, 17-2012-3, and 25-2012-516, to M.A.A.), NIH National Institute of Allergy and Infectious Diseases (AI42288, to M.A.A. and M.C.-S.), NIH National Institute of Diabetes and Digestive and Kidney Diseases (DK12572, DK72473, DK104211, to A.C.P.), The Leona M. and Harry B. Helmsley Charitable Trust, the Department of Veterans Affairs, and the Vanderbilt Diabetes Research and Training Center (DK20593).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Eisenbarth GS. Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360–1368
2. Atkinson MA. George S. Eisenbarth, 1947-2012. Diabetologia 2013;56:435–438
3. Bluestone JA, Harald K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293–1300
4. Peakman M. Immunological pathways to β-cell damage in type 1 diabetes. Diabet Med 2013;30:147–154
5. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69–82
6. Skysler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011;60:1–8
7. Greenbaum C, Atkinson MA. Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes. Diabetes 2011;60:693–694
8. Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetologia 2012;61:1323–1330
9. Skysler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med 2013;30:161–169
10. Ben Nasr M, D’Addio F, Usuelli V, Tezza S, Abdi R, Fiorina P. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 6 August 2014 [Epub ahead of print]. DOI: 10.1016/j.phrs.2014.07.004
11. Shoda IK, Young DL, Ramanujan S, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23:115–126
12. Todd JA, Knip M, Mathieu C. Strategies for the prevention of autoimmune type 1 diabetes. Diabet Med 2011;28:1141–1143
13. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013;9:92–103
14. Frederiksen BN, Steck AK, Kroehl M, et al. Evidence of stage- and age-related heterogeneity of non-HLA SNPs and risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young. Clin Dev Immunol 2013;2013:47657
15. Stanek K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013;132:1112–1122
16. Crume TL, Crandell J, Norris JM, et al. Timing of complementary food introduction and age at diagnosis of type 1 diabetes: the SEARCH Nutrition Ancillary Study (SNAS). Eur J Clin Nutr 2014;68:1258–1260
17. de Goffau MC, Fuentes S, van den Bogert B, et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 2014;57:1569–1577
18. Richardson SJ, Leete P, Dhayal S, et al. Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Reply to Hanisson SF, Korsgren S, Pontén F et al. [letter]. Diabetologia 2015;57:647–649
19. Arif S, Leete P, Nguyen V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014;63:3835–3845
20. Chen YG, Cabrera SM, Jia S, et al. Molecular signatures differentiate immune states in type 1 diabetic families. Diabetes 2014;63:3960–3973
21. Irn Veld P, Lievens D, De Grijse J, et al. Screening for insulin in adult autoantibody-positive organ donors. Diabetes 2007;56:2400–2404
22. Pugliesi A, Yang M, Kusmarteva I, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes 2014;15:1–9
23. Irn Veld P. Insulins in human type 1 diabetes: a comparison between patients and animal models. Semin Immunopathol 2014;36:569–579
24. Skowera A, Ladell K, McLaren JE, et al. β-Cell–specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes 2015;64:916–925
25. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-auto-reactive CD8 T cells in insulinic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012;209:51–60
26. Davis AK, DuBose SN, Haller MJ, et al.; TID Exchange Clinic Network. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015;38:476–481
27. Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, van Herrath MG. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 2014;63:3880–3890
28. Valle A, Giampracoron GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013;62:2072–2077
29. Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008;57:2555–2562
30. Bogdani M, Korpos E, Simeonovic CJ, Parish CR, Sorokin L, Wight TN. Extracellular matrix components in the pathogenesis of type 1 diabetes. Curr Diab Rep 2014;14:552
31. Krogvold L, Edwin B, Buanes T, et al. Detection of a low-grade enterovaliral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 2015;64:1682–1687
32. Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and β-cell apoptosis. Diabetes Obes Metab 2013;15(Suppl. 3):71–81
33. Tanaka S, Aida K, Nishida Y, Kobayashi T. Pathophysiological mechanisms involving aggressive islet cell destruction in fulminant type 1 diabetes. Endocr J 2013;60:837–845
34. Tracy S, Smithee S, Alhazmi A, Chapman N. Coxackievirus can persist in murine pancreas by deletion of 5′ terminal genomic sequences. J Med Virol 2015;87:240–247
35. Xia CQ, Peng R, Chernatynskaya AV, et al. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol 2014; 193:1024–1034

36. Wilson EB, Yamada DH, Elsasser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013;340:202–207

37. Sullivan BM, Tejario JR, de la Torre JC, Oldstone MB. Early virus-host interactions dictate the course of a persistent infection. PLoS Pathog 2015;11:e1004588

38. Tejario JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013;340:207–211

39. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005;53:1087–1095

40. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006;103:2334–2339

41. Dai C, Brissova M, Hang Y, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetologia 2012;55:707–718

42. Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocana A. Human β-cell proliferation and intracellular signaling part 2: still driving in the dark without a map. Diabetes 2014;63:819–831

43. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β-Cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111–117

44. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007;3:758–768

45. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012;97:3197–3206

46. Williams AJ, Thrower SL, Sequeiros IM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 2012;97:E2109–E2113

47. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease.

48. Montgomery EL, Atkinson MA, Kaddis JS. Pancreatic β-cell proliferation and intracellular signaling part 2: still driving in the dark without a map. Diabetes 2014;63:819–831

49. von Herrath M, Senda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988–994

50. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573–1579

51. Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest 2015;125:448–455

52. Richardson SJ, Willcox A, Bone AJ, Morgan F, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol 2011;33:9–21

53. Rigby MR, DiMeglio LA, Rendell MS, et al.; TIDAL Study Team. Targeting of memory T cells with alfacепlex in newly-onset type 1 diabetes (TIDAL study): 12 months results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284–294

54. Pope JE, Rampakakis E, Sampalis J. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. Semin Arthritis Rheum. 2008 September 24 [Epub ahead of print]. DOI: 10.1016/j.sar.2009.04.00

55. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D concepts and strategies. Clin Immunol 2013;149:279–285

56. Cefalu WT, Boulton AJ, Tamborlane WV, et al. Status of Diabetes Care: “It just doesn’t get any better . . . or does it?” Diabetes Care 2013;37:1782–1785

57. Chase HP, Lescheck E, Raflken-Mervis L, et al.; Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. ICAAN 2009;1:98–107

58. Knip M, Virtanen SM, Seppä K, et al.; Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010;363:1900–1908

59. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011;34:1303–1305

60. Knip M, Åkerblom HK, Becker D, et al.; TRIGR Study Group. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA 2014;311:2279–2287

61. Vaara O, Ilenon J, Ruohutla T, et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med 2012;166:608–614

62. Lamping E, Kliinghammer A, Scherbaum WA, et al.; DENIS Group. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes mellitus [letter]. N Engl J Med 2002;346:1692–1698

63. Ohta E, Björk E, Wallenstein M, et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004;27:2191–2197

64. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004;1:80–88

65. Crinò A, Schiaffini R, Manfrini S, et al.; IMDIAB Group. A randomized trial of nicotinamide and vitamin E in children with recent-onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 2004;150:719–724

66. Crinò A, Schiaffini R, Campanili P, et al.; IMDIAB Group. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent-onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005;18:749–754
83. Keymeulen B, Vandemeulebroecke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598–2608
84. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763–1769
85. Pitocco D, Crinó A, Di Stasio E, et al.; IMIDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMIDIAB XI). Diabet Med 2006;23:920–923
86. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007;23:920–923
87. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568–1576
88. Lazar L, Ofan R, Weinrib N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23:286–291
89. Schloot NC, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23:276–285
90. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909–1920
91. Herold KC, Gitelman S, Greenbaum C, et al.; Immune Tolerance Network ITN007A1 Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166–173
92. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009;32:2036–2040
93. Pescevitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143–2152
94. Mastrandrea L, Yu J, Behrens T, et al. Eta-nercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244–1249
95. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614–623
96. Radtke MA, Nermoen I, Kollind M, et al. Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of beta-cell function and autoimmunity but improves glycemic control. Diabetes Care 2010;33:589–594
97. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010;33:1443–1448
98. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protège study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487–497
99. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319–327
100. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412–419
101. Martin S, Herder C, Schloot NC, et al.; DIATOR Study Group. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 2011;6:e17554
102. Snarski E, Milczarczyk A, Casas R, et al. Independence of exogenous insulin following immunoblation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011;46:562–566
103. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012;366:433–442
104. Strom A, Kolb H, Martin S, et al.; DIATOR Study Group. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012;7:e33108
105. Li L, Shen S, Ouyang J, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012;97:1729–1736
106. Gu W, Hu J, Wang W, et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care 2012;35:1413–1419
107. Long SA, Rieck M, Sanda S, et al.; Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012;61:2340–2348
108. Moran A, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Canakinumab Study Group; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381:1905–1915